Healthcare
Zynex, Inc.(ZYXIQ)
Live Price
Offline$0.055
-8.33% today
Window Change
-97.70%
Window
Jun 23, 2025 โ Mar 26, 2026
- Market Cap
- $1.69M
- Revenue Growth
- +4.4%
- EPS Growth
- -65.3%
- Dividend Yield
- 0.0%
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 192 bars ยท Jun 23, 2025 โ Mar 26, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Zynex, Inc. (ZYXIQ) is a Healthcare stock with a market cap of $1.69M and listed on OTC. The stock last traded around $0.06 and down 97.7% across the available one-year price window (Jun 23, 2025 โ Mar 26, 2026). Baseline metrics include revenue growth of +4.4%, EPS growth of -65.3%, a dividend yield of 0.0%. What stands out right now is revenue +4.4%, EPS -65.3%, free cash flow -26.6% with operating margin -62.8% and ROIC -224.5%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ZYXIQ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+4.4% vs +7.6% peer median
Operating Margin
Below sector median
-62.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +4.4% and EPS is at -65.3%, with operating margin around -62.8%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 2 reported quarters, the stock averaged -2.5% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2025 Nov 17, 2025 | -115.8% | -25.7% | +29.2% | -39.8% |
2025 Jul 31, 2025 | -146.2% | -43.5% | -34.1% | -26.5% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZYXIQ
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
ZYXIQ Max Drawdown
-98.85%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ZYXIQ and SPY.
Company Overview
Zynex, Inc.
Other OTC
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain, and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; and M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body; and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, braces for rehabilitation support for knee and wrist, and Dynacomp for cold compression therapy. Further, it develops Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser photoplethysmographic patient monitoring device; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; and fluid monitoring and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado. On December 15, 2025, Zynex, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.
- Leadership
- Steven Lewis Dyson
- IPO Date
- Feb 25, 2004
- Employees
- 1.0k
- Street Address
- 9655 Maroon Circle
- Mailing
- Englewood, CO, 80112
- Region
- Englewood, CO, US
- Reporting Currency
- USD
- Investor Line
- 303 703 4906
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.0
- Price/Book
- โ
Growth
- Revenue
- +4.4%
- EPS
- -65.3%
- Free Cash Flow
- -26.6%
Profitability
- Gross Margin
- 71.6%
- Operating Margin
- -62.8%
- Net Margin
- -68.4%
- ROE
- -1807.0%
- ROIC
- -224.5%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.47
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.